Treatment Resistant Depression and Vagus Nerve Stimulation

Treatment Resistant Depression (TRD) Clinical Trial

— DepVNS  

Official title:

Resistant Depression and Vagus Nerve Stimulation : a Medico-economic, Multicenter, Randomized and Open Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05952674
• Other study ID #: APHP200066
• Status: Not yet recruiting
• Phase: N/A
• Start date: September 1, 2023
• Est. completion date: March 1, 2030

Study information

• Verified date: July 2023
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Philippe DOMENECH, MD, MSc
• Phone: (0) 1 45 65 76 65
• Email: philippe.domenech[@]ghu-paris.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Depression is a common illness, affecting 17% of the population over the course of a lifetime. A third of depressions relapses and progresses to recurrence and resistance to treatments. Despite the optimization of antidepressant medical strategies, 20 to 40% of depressions do not respond to treatment. This is particularly worrying as 6% of non-responder patients will die by committing suicide.

Depression has a major impact on quality of life, socio-professional functioning and healthcare consumption.

Sometimes, TRD is part of a bipolar illness. In this case, the challenge is even bigger because antidepressants are no well tolerated, further reducing the therapeutic options in case of resistance, the severity and duration of the depressive episodes are the main factors explaining the deterioration of the quality of life and the increasing cost of cares for these patients.

The standard treatment for TRD is electroconvulsive therapy (ECT), which results in a response in 60 to 70% of cases after a few weeks of treatment. However, the improvement is often transient and 40% of patients relapse within 6 months of the initial ECT session. Moreover, ECT is often not well tolerated. This therapeutic impasse therefore makes TRD a priority public health target to which it is urgent to provide a realistic medico-economical response.

The literature suggests that Vagus Nerve Stimulation (VNS) has unique kinetics of efficacy in depression, particularly in preventing long-term recurrences, and therefore responding to the lack of effective maintenance treatment in TRD. In fact, the benefits of VNS gradually accumulate over 12-24 months, which makes it complementary to more incisive treatments like ECT. Finally, its efficacy-tolerance profile appears to be similar in uni and bipolar TRD, giving VNS a potentially unique place in the therapeutic arsenal in psychiatry.

The DepVNS hypothesis is that VNS is a medico-economically efficient therapeutic option to overcome the therapeutic impasse in which patients suffering from uni and bipolar DR currently find themselves due to the frequency of relapses under treatment.

The primary objective is to estimate, from a collective point of view, the incremental cost-utility ratio of VNS to treat patients suffering from RD.

Description:

Depression is a common illness, affecting 17% of the population over the course of a lifetime. A third of depressions relapses and progresses to recurrence and resistance to treatments. Despite the optimization of antidepressant medical strategies, 20 to 40% of depressions do not respond to treatment. This is particularly worrying as 6% of non-responder patients will die by committing suicide. The term treatment-resistant depression (TRD) is used when two or more (and often many more) well conducted antidepressant treatments from different classes have failed to achieve remission.

Depression has a major impact on quality of life, socio-professional functioning and healthcare consumption. According to the World Health Organization (WHO), depression will be the second cause of healthcare costs in the world by 2020. RD alone accounts for 30 to 40% of the annual cost of depression.

Sometimes, TRD is part of a bipolar illness, a psychiatric condition characterized by the alternation of depressive and maniac episodes that affects 4% of the population. In this case, the challenge is even bigger because (1) antidepressants are no well tolerated, further reducing the therapeutic options in case of resistance, (2) the severity and duration of the depressive episodes are the main factors explaining the deterioration of the quality of life and the increasing cost of cares for these patients. Bipolar RD currently accounts for 20% of all psychiatric spending.

The standard treatment for TRD is electroconvulsive therapy (ECT), which results in a response in 60 to 70% of cases after a few weeks of treatment. However, the improvement is often transient and 40% of patients relapse within 6 months of the initial ECT session. Moreover, ECT is often not well tolerated because of the frequency and the intensity of the memory disorders associated, the repetition of anesthesia and hospitalizations and its social stigma. Refusals and requests to stop ECT are therefore common even when it is effective, as these constraints are sometimes experienced as being unbearable in the long-term. This therapeutic impasse therefore makes TRD a priority public health target to which it is urgent to provide a realistic medico-economical response.

The literature suggests that Vagus Nerve Stimulation (VNS) has unique kinetics of efficacy in depression, particularly in preventing the long-term recurrences, and therefore responding to the lack of effective maintenance treatment in TRD. In fact, the benefits of VNS gradually accumulate over 12-24 months, which makes it complementary to more incisive treatments like ECT. Finally, its efficacy-tolerance profile appears to be similar in uni and bipolar TRD, giving VNS a potentially unique place in the therapeutic arsenal in psychiatry. VNS has been approved for over 15 years as a treatment for RD in the Unites States and Great-Britain.

The hypothesis is that VNS is a medico-economically efficient therapeutic option to overcome the therapeutic impasse in which patients suffering from uni and bipolar DR currently find themselves due to the frequency of relapses under treatment.

The primary objective is to estimate, from a collective point of view, the incremental cost-utility ratio of VNS to treat patients suffering from RD.

The secondary objectives are evaluating the efficacy and the security of the VNS, as well as positioning the VNS in comparison with ECT that is currently the standard treatment for TRD.

This is a national multicenter comparative, open, randomized, controlled, two-parallel group clinical trial evaluating the medico-economic impact of VNS in resistant depression population. Patients (166) suffering from resistant depression will be enrolled over a 24-month period and will be randomized in a (1:1) ratio to receive either Vagus Nerve Stimulation (VNS) along with the Best Medical Treatment (VNS+BMT arm) or the Optimal Medical Treatment only (BMT arm).

Patients meeting all eligibility criteria will be enrolled in the study.

All subjects will be followed by the investigators or designee of the investigator during the whole study period by visits on site.

Number of visits/participant: Both arms will attend: selection visit (VS), inclusion visit (VI) and randomization visit (R), M0, M2, M4, M6, M8, M10, M12, M14, M16, M18, M20, M22 and M24. After the inclusion visit, the experimental arm (VNS + BMT) will further attend a neurosurgical and anesthetic consultation before being hospitalized for the VNS system placement. The patient will finally be hospitalized in psychiatry for about 5 days for switching the device on. If the target intensity has not been reached during this hospitalization, an adjustment visit is planned every month for 6 months in order to progressively increase the stimulation intensity until the target or a therapeutic response. If the target or the therapeutic response is obtained, the settings adjustments rhythm will be at the indiscretion of the psychiatrist. If at the end of the 6 first visits (M1 to M6), the target intensity couldn't be reached or in absence of a satisfying clinical response, a visit will be planned every 3 months (consultation or hospitalization) to keep optimizing the VNS.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 166
• Est. completion date: March 1, 2030
• Est. primary completion date: March 1, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients aged 18 years and older ;

• Childbearing women must have an efficient contraception for the whole study period

• Diagnosis of recurrent depressive trouble or persistent depressive disorder or bipolar disorder (according to DSM-5)

• Start of disorder (defined by the occurrence of the first thymus episode:

characterized depressive disorder or maniac episode with or without mixed characteristics) for 5 years or more

• At least one of the following criteria:

• Criterion A: current characterized depressive disorder and characterized depressive disorder for at least 12 months during the last 24 months despite at least four treatments lines at appropriate dosage and duration

• Criterion B: current treatment by ECT and criteria A before the start of the ECT treatment or ECT dependency criteria

• Patients who, after the nature of the study has been explained to them, have given written consent

Exclusion Criteria:

• Know pregnancy or breastfeeding

• Schizophrenia, schizoaffective disorder or persistent delusional disorder (DSM-5)

• Characterized depressive disorder with psychotic characteristics within 3 months before the inclusion (DSM-5)

• Concomitant participation to another interventional clinical trial, excepted eventual ancillary researches validated by the study scientific committee. Participation to non-interventional researches is allowed.

• Patients receiving enforced cares (ASPDT, ASPPI, ASPDRE, etc.)

• Non-affiliation to a social security regimen or any other social protection regimen

• Disability, according to the investigator, to understand the study or refusal to sign the study consent form (non-francophone patient, cognitive disorders)

• Anticipated disability to attend all the visits, treatments and measures planned by the protocol: severe personality disorder, severe substance addiction, severe intellectual development disorder. In any of those cases, the notion of severity is at the indiscretion of the investigator

Secondary Exclusion Criteria:

• Surgical contraindication to the VNS

• Positive ß-HCG (results obtained after the informed consent is signed but before the randomization)

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Treatment-Resistant
• Treatment Resistant Depression (TRD)

Intervention

Device:
• Vagus Nerve Stimulation (VNS)
The surgical intervention for the implantation of the VNS medical device is performed by a neurosurgeon under general anesthesia and lasts about an hour. Two incisions are made on the left: one incision to implant an electrode wrapped around the vagus nerve, the other incision to implant the stimulator. The electrode and the stimulator are connected by a cable tunneled. The cardiac tolerance is usually tested at the end of the surgery by turning on the neurostimulator for a few minutes. The stimulator is turned on about two weeks after the implantation, and after the neurosurgeon has checked the quality of healing. The settings used in first intention are standardized and derived from the parameters usually used for the treatment of epilepsies: a pulse width of 250µs, a stimulation frequency of 30Hz, and a 30sec stimulation cycle (ON) every 5min (OFF). Intensity is progressively increased by steps of 0.25mA to reach the 1.5-2mA range, depending on stimulation-induced side effects.

Other:
• Best Medical Treatment
Best Medical Treatment for resistant depression.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris	LivaNova

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cost-utility of VNS	Incremental cost-utility ratio of the Vagus Nerve Stimulation (group VNS + optimal medical treatment) in comparison to the control group (optimal medical treatment only) within 24 months of VNS placement	Month 24
Secondary	Efficacy of the VNS	Response rate (< 50% amelioration of the QIDS-SR baseline score) cumulative and non-cumulative	Month 24
Secondary	Efficacy of the VNS	Remission rate (QIDS-SR score = 5) cumulative and non cumulative	Month 24
Secondary	Efficacy of the VNS	CGI (Clinical Global Impression). Three scores: severity of the disease noted out of 7, overall improvement noted out of 7 and therapeutic index noted out of 16.	Month 24
Secondary	Efficacy of the VNS	EGF (Functioning Global Evaluation scale). Minimum: 0. Maximum: 100. The higher the score, the higher the level of psychological, social and occupational functioning.	Month 24
Secondary	Efficacy of the VNS	Number of weeks in depression, remission, (hypo)mania and number of major depressive episodes and (hypo)maniac episodes (DSM-5 criteria)	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Efficacy of the VNS	Average intensity of anxious symptoms : STAI-A (State-Trait Anxiety Inventory - Form A). Minimum: 20. Maximum: 80. A higher score indicates greater anxiety.	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Efficacy of the VNS	Average intensity of thymus symptoms : QIDS-SR (Quick Inventory of Depressive Symptomatology - Self Report). Minimum: 0. Maximum: 27. The higher the score, the worse the symptoms.	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Efficacy of the VNS	Average intensity of thymus symptoms : YMRS (Young Mania Rating Scale). Minimum: 0. Maximum: 60. The higher the score, the more severe the symptoms.	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Efficacy of the VNS	Average intensity of thymus symptoms : VAS mood (Visual Analogue Scale Mood). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his mood.	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Efficacy of the VNS	Average intensity of thymus symptoms : VAS motivation (Visual Analogue Scale Motivation). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his motivation.	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Efficacy of the VNS	Average intensity of depressive episodes : QIDS-SR (Quick Inventory of Depressive Symptomatology - Self Report). Minimum: 0. Maximum: 27. The higher the score, the worse the symptoms.	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Efficacy of the VNS	Average intensity of depressive episodes : VAS mood (Visual Analogue Scale Mood). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his mood.	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Efficacy of the VNS	Average intensity of depressive episodes : VAS motivation (Visual Analogue Scale Motivation). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his motivation.	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Efficacy of the VNS	Average duration of response periods (< 50% improvement in QIDS-SR baseline score).	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Efficacy of the VNS	Average intensity of symptoms during the response phases : QIDS-SR (Quick Inventory of Depressive Symptomatology - Self Report). Minimum: 0. Maximum: 27. The higher the score, the worse the symptoms.	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Efficacy of the VNS	Average intensity of symptoms during the response phases : VAS mood (Visual Analogue Scale Mood). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his mood.	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Efficacy of the VNS	Average intensity of symptoms during the response phases : VAS motivation (Visual Analogue Scale Motivation). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his motivation.	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Efficacy of the VNS	Average intensity of (hypo)maniac episodes: YMRS (Young Mania Rating Scale). Minimum: 0. Maximum: 60. The higher the score, the more severe the symptoms.	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Efficacy of the VNS	Average intensity of (hypo)manic episodes: VAS mood (Visual Analogue Scale Mood ). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his mood.	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Efficacy of the VNS	Average intensity of (hypo)manic episodes: VAS motivation (Visual Analogue Scale Motivation). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his motivation.	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Efficacy of the VNS	Average duration of depressive episodes (DSM-5 criteria) and (hypo)manic episodes	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Efficacy of the VNS	Interval between the major depressive episodes and interval between the (hypo)maniac episodes (DSM-5 criteria)	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Efficacy of the VNS	Number of treatments/month	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Efficacy of the VNS	Total cost of cares	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Efficacy of the VNS	Quality of life : Q-LES-Q-SF (Quality of Life Enjoyment and Satisfaction Questionnaire Short Form). Score out of 70 and percentage. The higher the score, the higher the quality of life.	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Efficacy of the VNS	Quality of life : SF-36 (Short Form 36 Health Survey). 8 dimensions each evaluated out of 100. The higher the score, the higher the quality of life.	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Efficacy of the VNS	Response rate (< 50% improvement in QIDS-C baseline score) cumulative and non-cumulative	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Efficacy of the VNS	Average C-SSRS scoring	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Impact of the VNS on ECT (electroconvulsive therapy)	Cumulative number of ECT session within 24 months	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Impact of the VNS on ECT (electroconvulsive therapy)	Number of maintenance ECT session within 24 months	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Impact of the VNS on ECT (electroconvulsive therapy)	Average duration to obtain a complete ECT withdrawal	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Impact of the VNS on ECT (electroconvulsive therapy)	Average time period between ECT during the maintenance phase	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Impact of the VNS on ECT (electroconvulsive therapy)	Proportion of patients withdraw from ECT	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Impact of the VNS on ECT (electroconvulsive therapy)	Number of treatments per year	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Impact of the VNS on ECT (electroconvulsive therapy)	Results of EVA memory disorders severity	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary	Impact of the VNS on ECT (electroconvulsive therapy)	Montreal Cognitive Assessment (MoCA) scoring	Months: 0, 12, 24
Secondary	Security of the VNS	1/ VNS failure rate with a subgroup analysis for patients concomitantly treated by ECT, 2/Reported serious and non-serious adverse events	Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24